Company: AMTX
Filing Date: 2025-11-07
Form Type: 10-Q
Source: 0001437749-25-033667
Chunk: 25

Company: AEMETIS, INC
Filing Date: 2025-11-07
Form: 10-Q
Item: Part I, Item 1
Chunk 25
---
01 per share. The warrants were fully exercised in  July 2025.
    
   The following table summarizes warrant activity during the nine months ending  September 30, 2025:

       Warrants Outstanding & Exercisable     Weighted - Average Exercise Price    Average Remaining Term in Years  
 Outstanding December 31, 2024   530  $11.70   4.78 
 Granted   226   0.01     
 Exercised   (226)  0.01     
 Outstanding September 30, 2025   530  $11.70   4.03 

   All of the above outstanding warrants are fully vested and exercisable as of  September 30, 2025.
    
   The fair value calculations for issued warrants are based on the following weighted average factors:

       For the nine months ended September 30,  
 Description   2025    2024  
 Dividend-yield   -%  -%
 Risk-free interest rate   3.99%  4.50%
 Expected volatility   90.48%  99.85%
 Expected life (years)   2.00   2.00 
 Exercise price per share  $0.01  $0.01 
 Market value per share on grant date  $2.59  $4.05 
 Fair value per share on grant date  $2.58  $4.04 

   11. Aemetis Biogas LLC – Series A Preferred Financing

       On
       December 20, 2018, Aemetis Biogas LLC ("ABGL") entered into a Series A Preferred Unit Purchase Agreement for the sale of Series A Preferred Units to Protair-
      X Americas, Inc., with Third Eye Capital acting as an agent. ABGL is authorized to issue
      11,000,000 common units and
      6,000,000 convertible, redeemable, secured, preferred membership units (the “Series A Preferred Units”). ABGL issued
      6,000,000 common units to Aemetis, Inc. at a stated value of
      $5.00 per common unit, and
      5,000,000 common units of ABGL are held in reserve as potential conversion units issuable to the Preferred Unit holder upon certain triggering events.